BARR PROFITS CLEAR ESTIMATES

arr Pharmaceuticals said strong sales of generic products and the performance of drug pacts with Teva (TEVA:Nasdaq ADR — commentary — research — Cramer's Take) and Kos Pharmaceuticals (KOSP:Nasdaq — commentary - research — Cramer's Take) helped lift fiscal first-quarter revenue 27% from a year ago. The Woodcliff Lake, N.J., drug company earned $83.2 million, or 78 cents a share, on revenue of $310 million for the quarter ended Sept. 30. A year ago, Barr earned $52.1 million, or 49 cents a share, and had revenue of $245 million.
The Street